Interim results from the ongoing OPTIMIZE-1 phase II study of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in first line metastatic pancreatic cancer demonstrate an objective response rate of 52% in 23 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe